Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of neonatal dosing of SERMs on CD1 mouse uterine gene expression at 3 months

ABSTRACT: Tamoxifen, a selective estrogen receptor modulator (SERM), is an effective treatment for breast cancers. In the CD-1 mouse model, neonatal oral dosing with tamoxifen leads to the development of adenomyosis. Both 4-hydroxyestradiol and tamoxifen can form DNA-reactive metabolites and may be involved in carcinogenesis of the uterus. After comparing the uterotrophic response of several SERMs the maximal uterotrophic doses of estradiol (100mg/kg) 4-hydroxyestradiol (385mg/kg) and tamoxifen (250mg/kg) were determined. Maximal uterotrophic doses were given orally to newborn CD-1 mice on days 1 – 4 after birth and gene and pathological changes examined in the uterus at 3 months after dosing. ERKOa knockout mice were dosed orally with tamoxifen (1mg/Kg) on days 1 – 4 after birth and uterine gene expression compared with CD-1 mice. Keywords: Comparison of SERMs at maximal uterotrophic doses

ORGANISM(S): Mus musculus

PROVIDER: GSE3625 | GEO | 2005/12/02

SECONDARY ACCESSION(S): PRJNA93731

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Effects of neonatal dosing of SERMs on CD1 mouse uterine gene expression at 3 months

Project description:Tamoxifen, a selective estrogen receptor modulator (SERM), is an effective treatment for breast cancers. In the CD-1 mouse model, neonatal oral dosing with tamoxifen leads to the development of adenomyosis. Both 4-hydroxyestradiol and tamoxifen can form DNA-reactive metabolites and may be involved in carcinogenesis of the uterus. After comparing the uterotrophic response of several SERMs the maximal uterotrophic doses of estradiol (100mg/kg) 4-hydroxyestradiol (385mg/kg) and tamoxifen (250mg/kg) were determined. Maximal uterotrophic doses were given orally to newborn CD-1 mice on days 1 â 4 after birth and gene and pathological changes examined in the uterus at 3 months after dosing. ERKOa knockout mice were dosed orally with tamoxifen (1mg/Kg) on days 1 â 4 after birth and uterine gene expression compared with CD-1 mice. Dosing groups: Estradiol (E2): 100mg/Kg 4-hydroxyestradiol (4OHE2): 385mg/Kg Tamoxifen : 250mg/Kg ERKO mice dosed with tamoxifen (1mg/Kg) 4 dosed animals and 4 controls for each treatment group. Uteri removed at 3 months after dosing and total RNA extracted. Controls were pooled. RNA labelling, hybridisation and analysis of fluorescence was carried out as described by Turton et al (2001). Cy3/Cy5 dye swap labelling was carried out on samples from each animal. Reference: Turton NJ et. al. (Oncogene (2001) 20, 1300-1306

2010-06-30 | E-GEOD-3625 | biostudies-arrayexpress

Gene Expression during Panobinostat Dosing

Project description:A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip

2018-01-30 | GSE109792 | GEO

MeHg-induced encephalopathy

Project description:In this dose series pregnant CD-1 (outbred) dams were exposed to methylmercury (MeHg) as monomethylmercuric chloride injected intraperitoneally on 9 d.p.c. Test doses were 10.0 mg/kg and below. This regimen induces symptoms of Fetal Minimata Disease (FMD) in term fetuses. Risks with respect to FMD for the various test doses were 10.0 mg/kg (40% risk), 5.0 mg/kg (20% risk), 2.5 mg/kg (NOAEL), and 1.25 mg/kg (subNOAEL). All measurements were on RNA from the embryonic forebrain (prosencephalon and surrounding tissue) at 3.0h post-treatment. Keywords = dose series Keywords = mercury Keywords = embryo Keywords = Fetal Minamata Disease Keywords: dose response

2004-03-11 | GSE1075 | GEO

2CdA-induced microphthalmia

Project description:In this dose series pregnant CD-1 (outbred) dams were exposed to the 2-chloro analogue of 2'-deoxyadenosine (a metabolic toxin) on 8 d.p.c. Test doses were developed from a teratological series for 2CdA-induced microphthalmia using BMDS modeling software from the US EPA. Benchmark doses for microarray analysis were: 5.0 mg/kg (25% risk), 2.5 mg/kg (5% risk), 1.25 mg/kg (NOAEL), and 0.625 mg/kg (subNOAEL). All measurements were on RNA from the embryo proper at 3.0h post-treatment. Keywords = dose series Keywords = 2-chloro-2'deoxyadenosine Keywords = embryo Keywords = microphthalmia Keywords: dose response

2004-03-11 | GSE1068 | GEO

Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice

Project description:Background: Methylphenidate (MPH) a psychostimulant prescribed to manage ADHD symptoms, has been increasingly prescribed to children not meeting the strict criteria for ADHD. It has also been misused as a “cognitive enhancer” and as an alternative to other psychostimulants. Here, we investigate whether chronic or acute administration of methylphenidate in mice at either 1mg/kg or 10mg/kg dosing, affects cell number and gene expression in the basal ganglion. Methodology/Principal findings: Through the use of stereological counting methods, we observed a significant reduction (~20%) in dopamine neuron numbers in the substantia nigra pars compacta (SNpc) following chronic administration of 10mg/kg MPH. This dosage of MPH also induced a significant increase in the number of morphologically-activated SNpc microglia. Additionally, exposure to either 1mg/kg or 10 mg/kg MPH increased the sensitivity of SNpc dopamine neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced oxidative stress. Unbiased gene screening employing Affymetrix GeneChip® HT MG-430 PM revealed changes in 115 and 54 genes in the substantia nigra (SN) of mice exposed to 1mg/kg and 10mg/kg MPH doses, respectively. Decreases in the mRNA levels of gdnf, dat1, vmat2 and th in the substantia nigra (SN) was observed with both acute and chronic dosing of 10mg/kg MPH. We also found an increase in mRNA levels of the pro-inflammatory genes il-6 and tnf-α in the striatum; although these were seen only at an acute dose of 10mg/kg and not following chronic dosing. Conclusion: Collectively our results suggest that chronic MPH usage in mice, especially at prolonged higher doses, has long-term neurodegenerative consequences.

2012-08-14 | GSE33619 | GEO

gene expression of ventral prostate in rat

Project description:Gene expression microarray analysis was performed on ventral prostate from normal adult rats, and adult rats treated BPA for 4 weeks(10 animals per group). Animals of 4 groups were treated with bisphenol-A (0,10, 30, or 90 ug/kg, i.g., daily) for 4 weeks, and the dosing volume is 10 ml/kg body weight. In this experiment, we only selected samples from two doses(0 and 10µg/kg) to analyze.

2014-01-15 | E-MTAB-2181 | biostudies-arrayexpress

Expression data from the liver of rat treated by Piperonyl butoxide and Dammar resin

Project description:Several studies have successfully detected hepatocarcinogenicity in rats based on gene expression data. Here, we constructed a model for detecting non-genotoxic (NGTX) hepatocarcinogens and predicted their MOAs in rats. Piperonyl butoxide (PBO) and Dammar resin (DAM) are NGTX hepatocarcinogens. Gene expression data in the liver treated by PBO and DAM was used for validation of constructed model. There are four and three dosing groups including control group in PBO and DAM, respectively. The replicates is three samples in each dosing group. Doses for PBO are 0, 500, 1000 and 1500 mg/kg and those for DMA are 0, 800 and 2000 mg/kg.

2015-07-29 | E-GEOD-71413 | biostudies-arrayexpress

Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice

2012-08-13 | E-GEOD-33619 | biostudies-arrayexpress

Transcription profiling of mouse uterine response to estrogen 17-beta-estradiol, the phytoestrogen genistein, and the synthetic estrogen diethylstilbestrol

Project description:We used gene expression profiling to investigate whether the molecular effects induced by estrogens of different provenance are intrinsically similar. In this article we show that the physiologic estrogen 17-beta-estradiol, the phytoestrogen genistein, and the synthetic estrogen diethylstilbestrol alter the expression of the same 179 genes in the intact immature mouse uterus under conditions where each chemical has produced an equivalent gravimetric and histologic uterotrophic effect, using the standard 3-day assay protocol. Data are also presented indicating the limitations associated with comparison of gene expression profiles for different chemicals at times before the uterotrophic effects are fully realized. We conclude that the case has yet to be made for regarding synthetic estrogens as presenting a unique human hazard compared with phytoestrogens and physiologic estrogens. Key words: diethylstilbestrol, estrogen, gene expression, genistein, microarray, phytoestrogen, toxicogenomics, uterus.

2022-11-20 | E-AFMX-13 | biostudies-arrayexpress

Transcription profiling by array of liver from rats treated with furan to study furan-induced cholangiofibrosis

Project description:Male Sprague Dawley Crl CD BR rats (190-240g, 6-8 weeks old), were obtained from Charles River, UK. They were given access to R&M No.1 diet and tap water ad libitum. Animals were housed 5/sex in solid bottom cages maintained at 21oC +/- 2oC, 12 h light and 12 h dark. All animals were acclimatised for at least 5 days prior to commencement of the study. Furan (CAS 110-00-9, Sigma-Aldrich Co. Ltd, >99 % pure was prepared in corn oil vehicle on the day of use and stored in sealed brown bottles. Furan was administered orally via gavage in corn oil at 30mg/kg (5 daily doses per week). Animals (n=5) were removed and sampled after 3 months of furan treatment. An off-dose recovery group was included at the 3 month time point (1 month off-dose) to enable assessment of lesion reversibility.

2008-04-01 | E-MEXP-1421 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data